Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT: Imatinib Dose and Combinations in CML
NCT00219739Phase 3Completed
- Sponsor
- CHU de Poitiers
- Start
- Sep 2003
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of imatinib, peginterferon alfa-2a, cytarabine in chronic myeloid leukemia (CML), sponsored by CHU de Poitiers. Started Sep 2003; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00219739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219739.